The Nippon India Pharma Fund has demonstrated strong performance, particularly over the past year, with a 1-year CAGR of 50.61%. Its focus on the pharmaceutical sector has yielded substantial returns, outperforming its benchmarks S&P BSE Healthcare TRI and S&P BSE Sensex TRI over various periods.
Nippon India Pharma Fund – Performance
- Latest NAV (as of 04 June 2024): ₹425.66
Overview
| Period | Nippon India Pharma Fund | B: S&P BSE Healthcare TRI | AB: S&P BSE Sensex TRI |
| 1 Year CAGR % | 50.61% | 54.16% | 23.23% |
| 3 Year CAGR % | 15.71% | 15.32% | 16.52% |
| 5 Year CAGR % | 22.71% | 20.60% | 15.13% |
| Since Inception % | 20.77% | 15.69% | 16.25% |
Nippon India Pharma Fund – Returns Analysis
| Period Invested For | ₹10,000 Invested On | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank Within Category |
| 1 Week | 28-May-24 | ₹9,772.70 | -2.27% | – | -3.86% | 44/182 |
| 1 Month | 03-May-24 | ₹9,886.70 | -1.13% | – | -1.63% | 83/181 |
| 3 Month | 04-Mar-24 | ₹9,978.60 | -0.21% | – | 1.57% | 113/176 |
| 6 Month | 04-Dec-23 | ₹11,247.10 | 12.47% | – | 14.60% | 86/165 |
| YTD | 01-Jan-24 | ₹10,794.80 | 7.95% | – | 9.20% | 84/169 |
| 1 Year | 02-Jun-23 | ₹14,409.50 | 44.09% | 43.67% | 37.62% | 46/145 |
| 2 Year | 03-Jun-22 | ₹16,148.40 | 61.48% | 26.99% | 26.12% | 47/133 |
| 3 Year | 04-Jun-21 | ₹14,465.80 | 44.66% | 13.08% | 18.61% | 83/121 |
| 5 Year | 04-Jun-19 | ₹29,640.70 | 196.41% | 24.24% | 18.94% | 18/101 |
| 10 Year | 04-Jun-14 | ₹48,832.80 | 388.33% | 17.17% | 14.89% | 17/78 |
| Since Inception | 05-Jun-04 | ₹4,25,668.60 | 4,156.69% | 20.62% | 17.14% | 45/179 |
Nippon India Pharma Fund – Portfolio Analysis
Sector Allocation
The Nippon India Pharma Fund predominantly invests in domestic equities within the pharmaceutical sector.
| Investment Type | Allocation (%) |
| Equity | 96.17% |
| Debt | 0% |
| Others | 3.83% |
Equity Holdings Breakdown
| Market Cap | Allocation (%) |
| Large Cap Stocks | 41.18% |
| Mid Cap Stocks | 25.33% |
| Small Cap Stocks | 8.85% |
| Other | 20.81% |
Nippon India Pharma Fund – Top 10 Stocks
| Stock | Sector | Value (Mn) | % of Total Holdings | 1M Change | 1Y Highest Holding | 1Y Lowest Holding | Quantity | 1M Change in Qty |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals | 9848.3 | 13.81% | -1.10% | 14.91% (Mar 2024) | 12.76% (Dec 2023) | 65.56 L | 0.00 |
| Lupin Ltd. | Pharmaceuticals | 6095.9 | 8.55% | 0.15% | 8.55% (Apr 2024) | 7.06% (May 2023) | 37.04 L | 0.00 |
| Cipla Ltd. | Pharmaceuticals | 4340.0 | 6.08% | -0.43% | 6.8% (Aug 2023) | 5.97% (Dec 2023) | 31.00 L | 0.00 |
| Apollo Hospitals Enterprises Ltd. | Hospital | 3858.5 | 5.41% | -0.38% | 5.98% (Jan 2024) | 3.59% (Aug 2023) | 6.49 L | 0.00 |
| Divis Laboratories Ltd. | Pharmaceuticals | 3605.4 | 5.05% | 0.69% | 5.29% (May 2023) | 4.29% (Oct 2023) | 9.01 L | 0.00 |
| Dr. Reddys Laboratories Ltd. | Pharmaceuticals | 3412.6 | 4.78% | 0.03% | 5.75% (Jul 2023) | 4.75% (Mar 2024) | 5.50 L | 0.00 |
| Gland Pharma Ltd. | Pharmaceuticals | 2909.0 | 4.08% | -0.32% | 5.06% (Dec 2023) | 2.43% (May 2023) | 17.00 L | 0.00 |
| J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals | 2642.3 | 3.70% | 0.26% | 3.9% (Sep 2023) | 3.26% (Feb 2024) | 13.87 L | -1.00 L |
| Zydus Lifesciences Ltd. | Pharmaceuticals | 2575.2 | 3.61% | -0.57% | 4.18% (Mar 2024) | 3.2% (Dec 2023) | 27.01 L | -2.53 L |
| Abbott India Ltd. | Pharmaceuticals | 2284.7 | 3.20% | -0.09% | 3.64% (May 2023) | 2.7% (Dec 2023) | 86.39 k | 0.00 |
Nippon India Pharma Fund – Risk Ratios
| Ratio | Value | Category Average |
| Standard Deviation | 12.56 (Low volatility) | 14.34 |
| Beta | 0.89 (High volatility) | 0.86 |
| Sharpe Ratio | 0.56 (Poor risk-adjusted returns) | 0.84 |
| Treynor’s Ratio | 0.08 (Poor risk-adjusted returns) | 0.14 |
| Jensen’s Alpha | 1.22 (Poor risk-adjusted returns) | 2.3 |
Suitable For
Investors with advanced knowledge of macro trends prefer to take selective bets for higher returns compared to other equity funds. These investors should be prepared for the possibility of moderate to high losses in their investments, even if the overall market is performing better.
Disclaimer: The information provided in this article is for educational and informational purposes only. It should not be considered investment advice or a recommendation to invest in any particular mutual fund or asset class. Past performance does not indicate future results, and investors should research and consult with a financial advisor before making investment decisions. Investing in mutual funds involves risks, including the possible loss of principal invested.
Note: Data as on June 5, 2024
Ahmedabad Plane Crash